CN110139861B - 作为cyp11a1(细胞色素p450单加氧酶11a1)抑制剂的吡喃衍生物 - Google Patents
作为cyp11a1(细胞色素p450单加氧酶11a1)抑制剂的吡喃衍生物 Download PDFInfo
- Publication number
- CN110139861B CN110139861B CN201780079479.4A CN201780079479A CN110139861B CN 110139861 B CN110139861 B CN 110139861B CN 201780079479 A CN201780079479 A CN 201780079479A CN 110139861 B CN110139861 B CN 110139861B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- pyran
- compound
- methyl
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211597796.4A CN116162084B (zh) | 2016-12-22 | 2017-12-21 | 作为cyp11a1抑制剂的吡喃衍生物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20166024 | 2016-12-22 | ||
| FI20166024 | 2016-12-22 | ||
| PCT/FI2017/050926 WO2018115591A1 (en) | 2016-12-22 | 2017-12-21 | Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211597796.4A Division CN116162084B (zh) | 2016-12-22 | 2017-12-21 | 作为cyp11a1抑制剂的吡喃衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110139861A CN110139861A (zh) | 2019-08-16 |
| CN110139861B true CN110139861B (zh) | 2022-12-30 |
Family
ID=61005837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211597796.4A Active CN116162084B (zh) | 2016-12-22 | 2017-12-21 | 作为cyp11a1抑制剂的吡喃衍生物 |
| CN201780079479.4A Active CN110139861B (zh) | 2016-12-22 | 2017-12-21 | 作为cyp11a1(细胞色素p450单加氧酶11a1)抑制剂的吡喃衍生物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211597796.4A Active CN116162084B (zh) | 2016-12-22 | 2017-12-21 | 作为cyp11a1抑制剂的吡喃衍生物 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10717726B2 (enExample) |
| EP (2) | EP3558981B1 (enExample) |
| JP (2) | JP7025432B2 (enExample) |
| KR (3) | KR102491308B1 (enExample) |
| CN (2) | CN116162084B (enExample) |
| AR (1) | AR110412A1 (enExample) |
| AU (2) | AU2017380282B2 (enExample) |
| CA (1) | CA3047370A1 (enExample) |
| CL (1) | CL2019001728A1 (enExample) |
| CO (1) | CO2019007321A2 (enExample) |
| CY (1) | CY1124461T1 (enExample) |
| DK (1) | DK3558981T3 (enExample) |
| EA (1) | EA039309B1 (enExample) |
| ES (1) | ES2880151T3 (enExample) |
| HR (1) | HRP20211255T1 (enExample) |
| HU (1) | HUE056540T2 (enExample) |
| IL (2) | IL267484B (enExample) |
| LT (1) | LT3558981T (enExample) |
| MA (2) | MA47102B1 (enExample) |
| MX (1) | MX388538B (enExample) |
| NZ (1) | NZ755395A (enExample) |
| PE (1) | PE20191137A1 (enExample) |
| PH (1) | PH12019550111A1 (enExample) |
| PL (1) | PL3558981T3 (enExample) |
| PT (1) | PT3558981T (enExample) |
| RS (1) | RS62198B1 (enExample) |
| SI (1) | SI3558981T1 (enExample) |
| TN (1) | TN2019000189A1 (enExample) |
| TW (2) | TWI762544B (enExample) |
| UA (1) | UA124640C2 (enExample) |
| WO (1) | WO2018115591A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
| WO2021229152A1 (en) | 2020-05-14 | 2021-11-18 | Orion Corporation | Cyp11a1 inhibitors |
| KR20230117187A (ko) | 2020-12-01 | 2023-08-07 | 오리온 코포레이션 | 전립선암 치료를 위한 cyp11a1 억제제로서 2,3-디히드로-4h-벤조[b][1,4]옥사진-4-일)(5-(페닐)-피리딘-3-일)메타논유도체 및 유사 화합물 |
| CA3210591A1 (en) * | 2021-03-01 | 2022-09-09 | Oskari KARJALAINEN | Process for the preparation of a cyp11a1 inhibitor and intermediates thereof |
| AR124985A1 (es) | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| JP2024511296A (ja) | 2021-03-01 | 2024-03-13 | オリオン・コーポレーション | ４ｈ－ピラン－４オンの構造を有するｃｙｐ１１ａ１阻害薬の固体形態 |
| IL309484A (en) | 2021-06-23 | 2024-02-01 | Orion Corp | A process for preparing a CYP11A1 inhibitor and its intermediates |
| EP4408426A1 (en) * | 2021-09-28 | 2024-08-07 | Orion Corporation | Cyp11a1 inhibitor for use in the treatment of prostate cancer |
| WO2023073285A1 (en) | 2021-10-28 | 2023-05-04 | Orion Corporation | Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor |
| EP4430027A1 (en) | 2021-11-10 | 2024-09-18 | Orion Corporation | Cyp11a1 inhibitors |
| US20250099451A1 (en) | 2022-01-20 | 2025-03-27 | Orion Corporation | Pharmaceutical composition of a cyp11a1 inhibitor |
| JP7645296B2 (ja) * | 2022-02-08 | 2025-03-13 | ディーエヌエフ カンパニー リミテッド | ヨウ素含有金属化合物およびこれを含む薄膜蒸着用組成物 |
| CN118307519A (zh) | 2023-01-06 | 2024-07-09 | 上海闻耐医药科技有限公司 | 一类cyp11a1抑制剂化合物及其制备方法和用途 |
| KR20240126916A (ko) | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
| AU2024242063A1 (en) | 2023-03-29 | 2025-10-09 | Xizang Haisco Pharmaceutical Co., Ltd. | Cyp11a1 inhibitor and use thereof |
| KR20250173540A (ko) | 2023-04-21 | 2025-12-10 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Cyp11a1 억제제 및 이의 용도 |
| WO2024230825A1 (en) * | 2023-05-11 | 2024-11-14 | Shenzhen Ionova Life Science Co., Ltd. | Novel compounds as cyp11a1 inhibitors and methods of use thereof |
| WO2025017072A1 (en) | 2023-07-19 | 2025-01-23 | Orion Corporation | Stable pharmaceutical compositions of a cyp11a1 inhibitor |
| WO2025021182A1 (en) * | 2023-07-27 | 2025-01-30 | Acerand Therapeutics (Hong Kong) Limited | Cyp11a1 inhibitors |
| WO2025051216A1 (zh) * | 2023-09-08 | 2025-03-13 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
| WO2025168117A1 (zh) * | 2024-02-08 | 2025-08-14 | 盛睿泽华医药科技（苏州）有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2025237211A1 (zh) * | 2024-05-11 | 2025-11-20 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的晶型物及其制备方法和应用 |
| WO2025247149A1 (zh) * | 2024-05-27 | 2025-12-04 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的盐及其晶型、其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074450A2 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| CN1747952A (zh) * | 2003-02-28 | 2006-03-15 | 埃克森希特医疗股份有限公司 | 治疗细胞增殖性疾病、视网膜病和关节炎的化合物和方法 |
| CN105339355A (zh) * | 2013-06-11 | 2016-02-17 | 奥赖恩公司 | 新的cyp17抑制剂/抗雄性激素 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176485A (ja) * | 1984-09-20 | 1986-04-18 | Ss Pharmaceut Co Ltd | 新規なγ−ピラン誘導体 |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2017
- 2017-12-20 AR ARP170103609A patent/AR110412A1/es active IP Right Grant
- 2017-12-21 KR KR1020197021256A patent/KR102491308B1/ko active Active
- 2017-12-21 SI SI201730841T patent/SI3558981T1/sl unknown
- 2017-12-21 PE PE2019001297A patent/PE20191137A1/es unknown
- 2017-12-21 CN CN202211597796.4A patent/CN116162084B/zh active Active
- 2017-12-21 EA EA201991513A patent/EA039309B1/ru unknown
- 2017-12-21 TW TW106145006A patent/TWI762544B/zh active
- 2017-12-21 CN CN201780079479.4A patent/CN110139861B/zh active Active
- 2017-12-21 PT PT178322509T patent/PT3558981T/pt unknown
- 2017-12-21 PL PL17832250T patent/PL3558981T3/pl unknown
- 2017-12-21 AU AU2017380282A patent/AU2017380282B2/en active Active
- 2017-12-21 US US16/472,377 patent/US10717726B2/en active Active
- 2017-12-21 RS RS20210994A patent/RS62198B1/sr unknown
- 2017-12-21 DK DK17832250.9T patent/DK3558981T3/da active
- 2017-12-21 HU HUE17832250A patent/HUE056540T2/hu unknown
- 2017-12-21 TW TW111114824A patent/TWI796205B/zh active
- 2017-12-21 LT LTEP17832250.9T patent/LT3558981T/lt unknown
- 2017-12-21 TN TNP/2019/000189A patent/TN2019000189A1/en unknown
- 2017-12-21 MA MA47102A patent/MA47102B1/fr unknown
- 2017-12-21 ES ES17832250T patent/ES2880151T3/es active Active
- 2017-12-21 KR KR1020237002074A patent/KR102826021B1/ko active Active
- 2017-12-21 MX MX2019007373A patent/MX388538B/es unknown
- 2017-12-21 KR KR1020257020993A patent/KR20250097993A/ko active Pending
- 2017-12-21 JP JP2019534192A patent/JP7025432B2/ja active Active
- 2017-12-21 NZ NZ755395A patent/NZ755395A/en unknown
- 2017-12-21 WO PCT/FI2017/050926 patent/WO2018115591A1/en not_active Ceased
- 2017-12-21 EP EP17832250.9A patent/EP3558981B1/en active Active
- 2017-12-21 HR HRP20211255TT patent/HRP20211255T1/hr unknown
- 2017-12-21 CA CA3047370A patent/CA3047370A1/en active Pending
- 2017-12-21 EP EP21165964.4A patent/EP3868756A1/en not_active Withdrawn
- 2017-12-21 MA MA055983A patent/MA55983A/fr unknown
- 2017-12-21 UA UAA201908272A patent/UA124640C2/uk unknown
-
2019
- 2019-06-19 IL IL267484A patent/IL267484B/en unknown
- 2019-06-20 CL CL2019001728A patent/CL2019001728A1/es unknown
- 2019-06-21 PH PH12019550111A patent/PH12019550111A1/en unknown
- 2019-07-09 CO CONC2019/0007321A patent/CO2019007321A2/es unknown
-
2020
- 2020-06-08 US US16/895,221 patent/US11098032B2/en active Active
-
2021
- 2021-05-28 AU AU2021203497A patent/AU2021203497B2/en active Active
- 2021-07-06 US US17/367,849 patent/US12030871B2/en active Active
- 2021-08-19 IL IL285729A patent/IL285729B/en unknown
- 2021-08-25 CY CY20211100760T patent/CY1124461T1/el unknown
-
2022
- 2022-02-10 JP JP2022019891A patent/JP7286825B2/ja active Active
-
2024
- 2024-05-24 US US18/674,603 patent/US20240308989A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074450A2 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| CN1747952A (zh) * | 2003-02-28 | 2006-03-15 | 埃克森希特医疗股份有限公司 | 治疗细胞增殖性疾病、视网膜病和关节炎的化合物和方法 |
| CN105339355A (zh) * | 2013-06-11 | 2016-02-17 | 奥赖恩公司 | 新的cyp17抑制剂/抗雄性激素 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110139861B (zh) | 作为cyp11a1(细胞色素p450单加氧酶11a1)抑制剂的吡喃衍生物 | |
| DK2748149T5 (en) | Pyridazinone compounds and their use as DAAO inhibitors | |
| CN115551831A (zh) | Cyp11a1抑制剂 | |
| CN105339355B (zh) | 新的cyp17抑制剂/抗雄性激素 | |
| CN102712626B (zh) | 具有pgds抑制作用的哌嗪化合物 | |
| CN104520292B (zh) | 磺酰基哌啶衍生物及它们用于治疗前动力蛋白介导的疾病的用途 | |
| BR112015009168B1 (pt) | Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica | |
| KR20230107800A (ko) | Hsd17b13 억제제 및 이의 용도 | |
| CN104736533B (zh) | Vegfr3抑制剂 | |
| CN108290881B (zh) | 治疗性化合物和其使用方法 | |
| BR122024021737A2 (pt) | Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos | |
| BR112019012906B1 (pt) | Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos | |
| HK40016600B (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors | |
| HK40016600A (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors | |
| HK1232542B (zh) | 吡唑基-3，4-二氢喹啉-2-酮醛固酮合酶抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |